Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Parnes

Showing results (111-120 of 131) with videos related to

Pageof 14
Sort By:
Allergy|October 17, 2023
Tezepelumab decreases airway epithelial IL-33 and T2-inflammation in response to viral stimulation in patients with asthmaA Sverrild, S Cerps, J J Nieto-Fontarigo, et al.
Arthritis and Rheumatism|September 30, 2008
Modulation of peripheral B cell tolerance by CD72 in a murine modelDaniel Hsieh-Hsin Li, Monte M Winslow, Thai M Cao, et al.
The Lancet. Respiratory Medicine|July 13, 2021
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trialSarah Diver, Latifa Khalfaoui, Claire Emson, et al.
International Immunology|August 23, 2005
Requirement for CD100-CD72 interactions in fine-tuning of B-cell antigen receptor signaling and homeostatic maintenance of the B-cell compartmentAtsushi Kumanogoh, Takashi Shikina, Chie Watanabe, et al.
NEJM Evidence|February 6, 2024
Tezepelumab and Mucus Plugs in Patients with Moderate-to-Severe AsthmaLars H Nordenmark, Åsa Hellqvist, Claire Emson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 21, 2007
Extracellular isoforms of CD6 generated by alternative splicing regulate targeting of CD6 to the immunological synapseMónica A A Castro, Marta I Oliveira, Raquel J Nunes, et al.
British Journal of Clinical Pharmacology|July 6, 2026
Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild-to-moderate asthmaAnna Lundahl, Jonathan Grigg, Lubna Abuqayyas, et al.
ACR Open Rheumatology|July 28, 2022
Safety and Biological Activity of Rozibafusp alfa, a Bispecific Inhibitor of Inducible Costimulator Ligand and B Cell Activating Factor, in Patients With Rheumatoid Arthritis: Results of a Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose StudyLubna Abuqayyas, Laurence E Cheng, Marcia Teixeira Dos Santos, et al.
The Journal of Allergy and Clinical Immunology|August 3, 2025
Anti-KIT antibody, briquilimab, induces mast cell apoptosis and depletion in non-human primatesSong Eun Lee, Hind Bouzid, Cheryl Kwan, et al.
Immunity|December 15, 2000
Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signalingA Kumanogoh, C Watanabe, I Lee, et al.
Pageof 14

Showing results (111-120 of 131) with videos related to

Sort By:
Pageof 14
Allergy|October 17, 2023
Tezepelumab decreases airway epithelial IL-33 and T2-inflammation in response to viral stimulation in patients with asthmaA Sverrild, S Cerps, J J Nieto-Fontarigo, et al.
Arthritis and Rheumatism|September 30, 2008
Modulation of peripheral B cell tolerance by CD72 in a murine modelDaniel Hsieh-Hsin Li, Monte M Winslow, Thai M Cao, et al.
The Lancet. Respiratory Medicine|July 13, 2021
Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trialSarah Diver, Latifa Khalfaoui, Claire Emson, et al.
International Immunology|August 23, 2005
Requirement for CD100-CD72 interactions in fine-tuning of B-cell antigen receptor signaling and homeostatic maintenance of the B-cell compartmentAtsushi Kumanogoh, Takashi Shikina, Chie Watanabe, et al.
NEJM Evidence|February 6, 2024
Tezepelumab and Mucus Plugs in Patients with Moderate-to-Severe AsthmaLars H Nordenmark, Åsa Hellqvist, Claire Emson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 21, 2007
Extracellular isoforms of CD6 generated by alternative splicing regulate targeting of CD6 to the immunological synapseMónica A A Castro, Marta I Oliveira, Raquel J Nunes, et al.
British Journal of Clinical Pharmacology|July 6, 2026
Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild-to-moderate asthmaAnna Lundahl, Jonathan Grigg, Lubna Abuqayyas, et al.
ACR Open Rheumatology|July 28, 2022
Safety and Biological Activity of Rozibafusp alfa, a Bispecific Inhibitor of Inducible Costimulator Ligand and B Cell Activating Factor, in Patients With Rheumatoid Arthritis: Results of a Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose StudyLubna Abuqayyas, Laurence E Cheng, Marcia Teixeira Dos Santos, et al.
The Journal of Allergy and Clinical Immunology|August 3, 2025
Anti-KIT antibody, briquilimab, induces mast cell apoptosis and depletion in non-human primatesSong Eun Lee, Hind Bouzid, Cheryl Kwan, et al.
Immunity|December 15, 2000
Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signalingA Kumanogoh, C Watanabe, I Lee, et al.
Pageof 14